Skip to main content
VBIO logo

Valion Bio, Inc. (VBIO) Stock Price & Analysis

Valion Bio, Inc. (VBIO) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.5399 (+9.96%), as of the Nov 19, 2026 trading session; market cap $1.16M.

Educational signal · not a buy or sell recommendation · How to read this

$0.5399 +$0.0489 (+9.96%) Market Cap $1.16M

Valion Bio, Inc. · VBIO

Malachite Innovations, Inc., formerly Vitality Biopharma, focuses on developing cannabinoid pharmaceuticals for inflammatory disorders.

Price as of Nov 19, 2026

Key Statistics

30 of 100

MoonshotScore v2 · Valion Bio (VBIO)

Weak
Business Quality Solid (70)
Financial Safety Fragile (5)
Valuation Bubble (11)
Growth Durability Shrinking (11)
Momentum Falling (11)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Solid; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.

Earnings yield is the main valuation drag relative to sector peers.

  • quarterly revenue $146,000 (Q3 FY2026, quarter ended Sep 30, 2025)
  • EPS beat 8 of the last 8 reports
  • Altman Z -4.49 · Piotroski F 2

Holding back: balance-sheet strain, a rich price, soft growth, weak price trend

Helping: business quality

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for VBIO (57 recorded, newest six shown)
RecordedScoreBand
28Weak
28Weak
28Weak
28Weak
30Weak
30Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.5399
Change on the day+9.96%
52-week range$0.4715 – $67.50
Market capitalisation$1.16M—
Shares traded on the day420.6K

Price & events

Other perspectives

Council score for Valion Bio (VBIO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Negative
Growth Durability Negative
Momentum Negative

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Weak
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Sep 6, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 6, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Valion Bio (VBIO), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Valion Bio, Inc. (VBIO) is the company analyzed here. It employs 52 people and is led by Michael R. Cavanaugh. In Q3 FY2026 it reported revenue of $146,000 and net income of -$3M. The market values it at $1.16M.

2 · Latest results

What do the latest results show for Valion Bio (VBIO)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $146,000. Against analyst estimates the company has EPS beat 8 of the last 8 reports.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$146,000-$3M-$1.97 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Valion Bio (VBIO)?

Short answer · as of

The MoonshotScore pillars rate business quality as strengths. What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -4.49 · Piotroski F 2. Trailing ratios: ROA -57.7% · current ratio 1.11.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -4.49 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Valion Bio compare with its peers?

Short answer

Valion Bio's score ranks 11th of 11 in the bounded comparison shown, against 10 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.07 Nov 19, 2026$540M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.88 Nov 19, 2026$178M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.28 Nov 19, 2026$545M68 5-pillar Nov 18, 2026
Indaptus Therapeutics, Inc. (INDP) Same industry, near in market value$3.13 Nov 19, 2026$481M60 5-pillar Nov 18, 2026
Cybin Inc. (HELP) Same industry, near in market value$6.78 Nov 19, 2026$541M60 5-pillar Nov 18, 2026
Valion Bio (VBIO) — this page$0.5399$1.16M30
American Hemp Ventures, Inc. (AMHV) Named competitor$0.98 Nov 13, 2026$16.5M— Model unavailable
Antisense Therapeutics Limited (ATHJF) Named competitor$0.01 Oct 2, 2026$19.6M— Model unavailable

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 22, 2026

Transactions
6
Identified insiders
2
Purchases
0
Sales
0
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held VBIO in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported VBIO in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Valion Bio (VBIO)?

Read these with our analysis →

Common Questions About VBIO

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for VBIO?

VBIO carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is VBIO a good stock to buy?

Stock Expert AI does not rate VBIO buy, sell or hold. Valion Bio, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the VBIO stock price today?

The last price recorded for Valion Bio, Inc. (VBIO), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for VBIO?

Valion Bio, Inc. (VBIO) holds a MoonshotScore in the low range. This could include conditions such as arthritis, multiple sclerosis, and Crohn's disease. Not financial advice.

How frequently does VBIO data refresh on this page?

VBIO's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven VBIO's recent stock price performance?

Valion Bio, Inc. (VBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider VBIO overvalued or undervalued right now?

Valion Bio, Inc. (VBIO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research VBIO before investing?

Before investing in Valion Bio, Inc. (VBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding VBIO to a portfolio?

No dossier-level strength is on record for Valion Bio, Inc. (VBIO) yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.